Diacerein - TWi Biotechnology

Drug Profile

Diacerein - TWi Biotechnology

Alternative Names: AC-201; AC-201 Controlled release tablet; AC-201CR; AC-203

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator TWi Biotechnology; TWi Pharmaceuticals
  • Developer TWi Biotechnology
  • Class Anthraquinones; Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Small molecules
  • Mechanism of Action Caspase 1 inhibitors; Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Epidermolysis bullosa; Gout; Joint disorders; Type 2 diabetes mellitus
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 05 Oct 2016 Efficacy data from a phase I trial in Epidermolysis Bullosa released by Castle Creek Pharmaceuticals ,
  • 03 Oct 2016 Phase-II clinical trials in Epidermolysis bullosa (In Children) in Austria (Topical) before October 2016
  • 03 Oct 2016 Final safety and efficacy data from a phase II trial in Epidermolysis Bullosa (In Children) released by Castle Creek Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top